Methods:Healthy controls n:25 (Group-I) and patients n:18, (Group-IIA: before omalizumab and Group- IIB: after omalizumab (after a year)).The concentrations of chemerin in the serum were measured using commercially available ELISA kits (Human Chemerin Elisa kit, BioVendor-Laboratorni Medicina AS, Cat No.RD191136200R, Brno, Czech Republic). The concentrations of irisin in the serum were measured using commercially available ELISA kits (Human Irisin Elisa kit, BioVendor-Laboratorni Medicina AS, Cat No. RAG018R, Brno, Czech Republic).Results were presented as mean ± SEM and mean ± SD. Comparison of parameters between the two groups was performed using Independent Samples T test. The relationship between the variables was determined using Pearson correlation analysis. Statistical significance was defined as p < 0.05. Statistical analyses were performed using SPSS 18.0 (IBM Corporation, New York, USA)..
Results:Chemerin levels(ng/mL) were significantly higher in severe persistent asthma patients compared to healthy volunteers.
Endogenous sources of chemerin include white fat, the liver, the platelet and PVAT. Chemerin is initially produced as a 163 amino acid precursor (pro-chemerin, TIG2) and processing of prochemerin by proteases is considered the key regulatory mechanism affecting chemerin concentration. Proteases that activate prochemerin include elastase, tryptase, cathepsin G, plasmin and carboxypeptidase N and B. We think that, Chemerin have an important role in patients with severe persistent asthma.